(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ONCOPOINT

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

ONCOPOINT

ST13

US500000090340914

Class

5

Filing

90340914

Registration

6798646

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

29

Latest update

07/19/2022

Trademark type

Combined

Nice classes

5

Filing date

11/24/2020

Registration date

07/19/2022

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/19/2022

Last transaction

07/19/2022

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

04/28/2021

First use in commerce

04/28/2021

Drawing code

3

Owner type

16

Owner location

Conshohocken, PA, US

Examiner

BLANE, SUZANNE

Law office

M50

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the literal element "OncoPoint" partially overlaid on a circular shape formed with curved lines of dots of various sizes.

Holders and representatives

Holders

BluePoint Intellectual Property, LLC

Representatives

Patrick C. Stephenson Kutak Rock LLP

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for use in treating human diseasesthe treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of oncologic conditions; drug products for oncology related conditionsdrugs in finished dosage form; anti-cancer agents; injectable anti-cancer agents; injectable medicines for use in oncology; antiemetic preparations

Publications

History of USPTO decisions and trademark events.

29 publications found

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

07/19/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

07/19/2022

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

06/14/2022

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

06/13/2022

SUPC

STATEMENT OF USE PROCESSING COMPLETE

05/26/2022

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

05/26/2022

IUAF

USE AMENDMENT FILED

05/13/2022

EISU

TEAS STATEMENT OF USE RECEIVED

05/13/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

12/17/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/17/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/17/2021

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

12/14/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/19/2021

PUBO

PUBLISHED FOR OPPOSITION

10/19/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/29/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/11/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

09/08/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

09/08/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

09/08/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

06/03/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/03/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

06/03/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

05/12/2021

GNRT

NON-FINAL ACTION E-MAILED

05/12/2021

CNRT

NON-FINAL ACTION WRITTEN

05/12/2021

DOCK

ASSIGNED TO EXAMINER

05/07/2021

MDSC

NOTICE OF DESIGN SEARCH CODE E-MAILED

02/02/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/30/2021

NWAP

NEW APPLICATION ENTERED

11/27/2020

Continuous trademark protection

Get notified about every new filing that threatens ONCOPOINT or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.